Table 2.
Type of chemotherapy administered and best RECIST and WHO responses
| Therapy administered | Lines of treatment given |
RECIST PR |
RECIST SD |
RECIST PD |
Median PFS† by RECIST (months), 95% CI |
WHO PR |
WHO SD |
WHO PD |
Median PFS† by WHO (months), 95% CI |
|---|---|---|---|---|---|---|---|---|---|
|
Anthracycline-
containing |
35 | 13 (37%) | 18 (51%) | 4 (11%) | * | 12 (34%) | 17 (43%) | 6 (23%) | * |
| Hormonal therapy | 26 | 6 (23%) | 17 (65%) | 3 (12%) | 12.0 (5.0-19.0) | 6 (23%) | 17 (65%) | 3 (12%) | 13.5 (6.8-20.2) |
|
Tyrosine Kinase
Inhibitor |
35 | 3 (9%) | 25 (71%) | 7 (20%) | 26.8 (0-61.4) | 2 (6%) | 22 (63%) | 11 (31%) | 21.4 (0-43.0) |
| DTIC or temozolomide | 16 | 2 (13%) | 12 (75%) | 2 (13%) | 14.3 (5.3-23.3) | 1 (6%) | 10 (63%) | 5 (31%) | 9.0 (0-19.2) |
|
Methotrexate (single
agent) |
12 | 4 (33%) | 6 (50%) | 2 (17%) | 9.4 (*) | 4 (33%) | 4 (33%) | 4 (33%) | * |
| Other cytotoxic agents | 8 | 0 | 7 (88%) | 1 (12%) | 3.7 (0-9.8) | 0 | 7 (88%) | 1 (12%) | 2.3 (0.5-4.1) |
|
Vinca-containing
combination |
10 | 2 (20%) | 6 (60%) | 2 (20%) | * | 2 (20%) | 5 (50%) | 3 (30%) | * |
| TOTAL | 142 | 30 (21%) | 91 (64%) | 21 (14%) | 14.1 (5.5-22.7) | 27 (19%) | 82 (58%) | 33 (23%) | 15.0 (5.6-24.4) |
†
Kaplan-Meier estimate
*
Median not reached, or not reached until last patient progressed, giving a meaningless value for the median or 95% CI.
CI: confidence interval